1
|
Koumarianou A, Ntavatzikos A, Vourli G, Symeonidis D, Vallilas C, Xynogalos S, Boukovinas I, Papaxoinis G, Demiri S, Kampoli K, Oikonomopoulos G, Giannakakou M, Samantas E, Res E, Androulakis N, Karamouzis M, Souglakos J. P-50 RETRO-TAS, a retrospective observational study of rifluridine/tipiracil in chemorefractory metastatic colorectal cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
2
|
Vourli G, Papatheodoridis G, Raptopoulou M, Dalekos GN, Hounta A, Nikolopoulou G, Zouboulis-Vafeiadis I, Manesis E, Kitis G, Gogos C, Ketikoglou I, Hatzis G, Vasilialdis T, Karatapanis S, Mimidis K, Drakoulis C, Touloumi G. Association of antiviral therapy with reduced disease progression in chronic Hepatitis B patients: Results from a nation-wide cohort study. Hippokratia 2016; 20:214-221. [PMID: 29097888 PMCID: PMC5654439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
BACKGROUND AND AIMS Although effective treatment in terms of inducing virological and biochemical response for chronic hepatitis B (CHB) is available, its effect on the clinical course of the disease has not yet been accurately estimated. Objective of this study was to evaluate the effect of antiviral therapy and its type [interferon +/- nucleos(t)ide analogs (NAs) vs. NAs] on the occurrence of a clinical event (liver decompensation, liver transplant, hepatocellular carcinoma and death from a liver-related cause) in CHB patients. METHODS The study population was derived from the HEPNET-Greece, a nationwide cohort study aimed to evaluate the current epidemiological course of viral hepatitis. To account for time-dependent confounding, Cox marginal structural models were used to analyze data. RESULTS Thirty out of 2,125 eligible patients experienced a clinical event during their follow-up. When comparing treated to untreated individuals, the hazard ratio (HR) for a clinical event was 0.39 (95% CI: 0.16-0.98; p =0.044) in the whole sample, whereas there were indications of a more intense effect in the subgroup of patients with cirrhosis at presentation (HR =0.16, 95% CI: 0.02-1.21; p =0.075). The effect of Interferon initiated treatment was not significantly different of that of NAs. There was some evidence, albeit not statistically significant, of a protective treatment effect on hepatocellular carcinoma development (HCC). CONCLUSIONS Data from observational studies can provide useful inference, provided they are analyzed appropriately. The current study has shown that the available treatment options for CHB offer a significant clinical benefit to CHB infected individuals. Hippokratia 2016, 20(3): 214-221.
Collapse
Affiliation(s)
- G Vourli
- Department of Hygiene, Epidemiology and Medical Statistics, Athens University Medical School, Athens, Greece
| | - G Papatheodoridis
- Department of Gastroenterology, Athens University Medical School, "Laiko" General Hospital of Athens, Athens, Greece
| | - M Raptopoulou
- 4 Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - G N Dalekos
- Department of Medicine & Research Laboratory of Internal Medicine, School of Medicine, University of Thessaly, Larissa, Greece
| | - A Hounta
- 4 Department of Internal Medicine, General University Hospital "Attikon", Athens, Greece
| | | | - I Zouboulis-Vafeiadis
- First Department of Propaedeutic Medicine, Athens University Medical School "Laiko" General Hospital of Athens, Athens, Greece
| | - E Manesis
- Division of Internal Medicine, Athens University Medical School, Athens, Greece
| | - G Kitis
- Gastroenterology Clinic, General Hospital "G. Papanikolaou", Thessaloniki, Greece
| | - C Gogos
- Department of Infectious Diseases, Patras University Hospital, Patras, Greece
| | - I Ketikoglou
- Department of Internal Medicine, "Hippocration" General Hospital, Athens, Greece
| | - G Hatzis
- Department of Pathophysiology, University of Athens, Athens, Greece
| | - T Vasilialdis
- 3Department of Internal Medicine, Aristotle University of Thessaloniki, "Papageorgiou" Hospital, Thessaloniki, Greece
| | - S Karatapanis
- Department of Internal Medicine, General Hospital of Rhodes, Rhodes, Greece
| | - K Mimidis
- Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece
| | - C Drakoulis
- 2 Department of Internal Medicine, General Hospital of Nikaia, Athens, Greece
| | - G Touloumi
- Department of Hygiene, Epidemiology and Medical Statistics, Athens University Medical School, Athens, Greece
| |
Collapse
|
3
|
Koutras A, Gerolymos M, Kontogeorgou E, Iconomou G, Vourli G, Tsiata E, Makatsoris T, Chrysanthopoulos C, Kalofonos H. Phase II Study of Irinotecan plus Leucovorin and Bolus 5-Fluorouracil as First- or Second-Line Chemotherapy in Patients with Advanced Gastric or Esophageal-Gastric Junction Adenocarcinoma. J Chemother 2013; 19:724-30. [DOI: 10.1179/joc.2007.19.6.724] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
4
|
Bamias A, Karina M, Papakostas P, Kostopoulos I, Bobos M, Vourli G, Samantas E, Christodoulou C, Pentheroudakis G, Pectasides D, Dimopoulos MA, Fountzilas G. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol 2010; 65:1009-21. [DOI: 10.1007/s00280-010-1256-6] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2009] [Accepted: 01/12/2010] [Indexed: 12/25/2022]
|
5
|
Mountzios G, Dimopoulos M, Bamias A, Vourli G, Kalofonos H, Aravantinos G, Fountzilas G, Papadimitriou C. 8001 Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Co-operative Oncology Group (HeCOG) study. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71523-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
6
|
Mountzios G, Dimopoulos M, Bamias A, Vourli G, Kalofonos H, Aravantinos G, Fountzilas G, Papadimitriou C. Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol 2009; 20:1362-8. [DOI: 10.1093/annonc/mdn797] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
7
|
Dimitrakakis C, Keramopoulos D, Vourli G, Gaki V, Bredakis N, Keramopoulos A. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer. Climacteric 2009; 8:342-51. [PMID: 16390769 DOI: 10.1080/13697130500345216] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
OBJECTIVES This observational, prospective, open, non-randomized study was designed to assess the safety and efficacy of tibolone for the treatment of climacteric symptoms in women with a history of breast cancer. METHODS A total of 156 women who had been treated for breast cancer and had received tamoxifen for 5 years participated in the study. One month after stopping tamoxifen, 52 women started taking tibolone while the rest served as untreated controls (n = 104). They were followed up (mean duration 61 months) for climacteric symptoms, cancer recurrence rate, breast density, endometrial thickness and adverse events. RESULTS There was no difference in cancer recurrence rate between the two groups. Breast density was not affected. Tibolone treatment alleviated climacteric symptoms and positively affected sexual problems. Endometrial thickness was not adversely affected by treatment and there was a low incidence of adverse events. CONCLUSIONS Tibolone was effective in the treatment of climacteric symptoms and well tolerated in a group of 52 women with a history of breast cancer. The cancer recurrence rate in the tibolone group was comparable to that of untreated controls. It should be noted that the limitations of the study design and the small number of events preclude any definitive conclusions about the effects of tibolone on breast cancer recurrence in general clinical practice. There were no breast-related adverse effects, and overall safety and tolerance were similar to those of the general population of postmenopausal women treated with tibolone.
Collapse
Affiliation(s)
- C Dimitrakakis
- Breast Center, Iaso Women's Health Hospital, Marousi, Athens, Greece
| | | | | | | | | | | |
Collapse
|
8
|
Papadimitriou CA, Kalogeras KT, Wirtz RM, Briasoulis E, Hennig G, Vourli G, Stropp U, Gogas H, Galani E, Samantas E, Makatsoris T, Fountzilas G. Elevated mRNA expression of herstatin predicts poor outcome in patients with high-risk early breast cancer. A possible molecular predictor of treatment benefit in the context of a Hellenic cooperative oncology group trial. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-6066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #6066
Background: Herstatin is a naturally occurring product of the HER2 gene generated by alternative mRNA splicing. It functions as a secreted inhibitor that binds to the extracellular domains of EGFR and HER2, disrupting multiple receptor combinations in response to a variety of ligands. This mode of action supports the potential utility of herstatin in the development of novel therapeutics against breast cancer. The aim of the present study was to evaluate the association of herstatin with HER family expression at the m-RNA level, as well as with other clinicopathological characteristics of patients with high-risk operable breast cancer enrolled in a randomized phase III trial. The effect of herstatin on disease-free survival (DFS) and overall survival (OS) was also investigated.
 Patients and Methods: 595 high-risk breast cancer patients were treated with anthracycline-based chemotherapy in the adjuvant setting (HE10/97 trial). This was a two-arm trial (E-CMF vs. E-T-CMF) investigating postoperative dose-dense sequential chemotherapy with epirubicin (E) followed by CMF with or without paclitaxel (T). RNA was extracted from 279 formalin-fixed paraffin-embedded tumor tissue samples followed by kinetic one-step RT-PCR for assessment of mRNA expression of herstatin, EGFR, HER2, HER3, and HER4. Values of RNA above the median were considered as positive expression, except for EGFR, where the 75th percentile was used as a cut-off. DFS and OS were estimated by the Kaplan-Meier method and compared using the log-rank test. Cox analysis for DFS and OS was also performed.
 Results: Positive herstatin expression was found to be significantly associated with ductal histology (χ2 test, p=0.004), and marginally associated with infiltrated lymph nodes (p=0.062). Furthermore, herstatin was found to be strongly correlated with HER2 expression (r=0.783, p<0.001) and weakly correlated with HER3 expression (r=0.144, p=0.02). Positive herstatin expression was associated with poor DFS and OS (log-rank, p=0.004 and 0.008, respectively). This remained unchanged when adjusted for treatment group, whereas no interaction between herstatin and treatment was identified. Interaction of HER2 overexpression (>75th percentile) with herstatin was found to be significant for OS (Wald, p=0.03), thus implying a possible prophylactic effect of herstatin in the subgroup of patients with HER2 overexpression.
 Conclusions: Herstatin was shown to be associated with a poor prognosis. Given the high correlation between herstatin and HER2, this finding may reflect the effect of HER2 on patient's prognosis. Our results suggest that the effect of herstatin may be altered in case of HER2 overexpression. This hypothesis should be investigated in future studies, focusing in patients with HER2 overexpression.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6066.
Collapse
Affiliation(s)
| | - KT Kalogeras
- 1 Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
| | - RM Wirtz
- 2 Siemens Healthcare Diagnostics, Cologne, Germany
| | - E Briasoulis
- 1 Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
| | - G Hennig
- 2 Siemens Healthcare Diagnostics, Cologne, Germany
| | - G Vourli
- 1 Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
| | - U Stropp
- 2 Siemens Healthcare Diagnostics, Cologne, Germany
| | - H Gogas
- 1 Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
| | - E Galani
- 1 Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
| | - E Samantas
- 1 Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
| | - T Makatsoris
- 1 Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
| | - G Fountzilas
- 1 Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
| |
Collapse
|
9
|
Papadimitriou CA, Markaki S, Lianos E, Peitsidis P, Vourli G, Nikitas N, Vlachos G, Rodolakis A, Antsaklis A, Dimopoulos MA. Clinicopathological features of primary fallopian tube carcinoma: a single institution experience. EUR J GYNAECOL ONCOL 2009; 30:389-395. [PMID: 19761129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
PURPOSE OF INVESTIGATION Primary fallopian tube carcinoma (PFTC) is a rare malignancy with only few data existing on the impact of prognostic factors. METHODS We retrospectively analyzed 26 patients. Tissue blocks were reviewed and sections were stained for vascular endothelial growth factor (VEGF), matrix metalloproteinases 2 and 9 (MMP-2, MMP-9), tissue inhibitors of metalloproteinases 1 and 2 (TIMP-1, TIMP-2), c-erbB-2, estrogen (ER), and progesterone receptors (PgR). RESULTS Reactivity for VEGF, ER, PgR, MMP-2, MMP-9, TIMP-1, TIMP-2 and c-erbB-2 was observed in 85%, 46%, 27%, 11.5%, 58%, 0%, 23% and 8% of specimens, respectively. None of the markers studied displayed prognostic significance. Regarding clinical prognostic factors, the hazard ratio (HR) for progression and death for patients with tumor residuum > 2 cm was 5.24 (p < 0.01) and 11.19 (p < 0.005), respectively. Patients with advanced stage disease had a HR of 12.55 (p < 0.05) for progression, while the HR for death was not found to be statistically significant. CONCLUSION None of the biomarkers studied seems to influence survival. Early-stage disease and optimal debulking are associated with improved outcome.
Collapse
Affiliation(s)
- C A Papadimitriou
- Department of Clinical Therapeutics, "Alexandra" Hospital, University of Athens School of Medicine, Greece.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Kalofonos HP, Bamias A, Koutras A, Papakostas P, Basdanis G, Samantas E, Karina M, Misailidou D, Pisanidis N, Pentheroudakis G, Economopoulos T, Papadimitriou C, Skarlos DV, Pectasides D, Stavropoulos M, Bafaloukos D, Kardamakis D, Karanikiotis C, Vourli G, Fountzilas G. A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study. Eur J Cancer 2008; 44:1693-700. [PMID: 18639450 DOI: 10.1016/j.ejca.2008.05.025] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2008] [Revised: 05/26/2008] [Accepted: 05/29/2008] [Indexed: 01/15/2023]
Abstract
The primary objective was to compare the 3-year survival of rectal cancer patients randomised postoperatively to irinotecan (IRI), Leucovorin (LV) and bolus 5-fluorouracil (5FU) or LV-bolus 5FU with radiotherapy. Secondary objectives included disease-free survival, local relapse and toxicity. The study included 321 eligible patients. The treatment consisted of weekly administration of IRI 80 mg/m(2) intravenously (IV), LV 200 mg/m(2) and 5FU 450 mg/m(2) bolus (arm A) versus LV 200 mg/m(2) and 5FU 450 mg/m(2) IV bolus (arm B). One cycle included four infusions and treatment was continued for a total of six cycles. The first cycle was followed by pelvic irradiation plus 5FU. There were no differences between the arms in 3-year overall, disease-free and local relapse-free survival. Grades 3 and 4 toxicity was similar in both the arms with the exception of leucopaenia, neutropaenia and alopecia, which were higher in the IRI arm. IRI added to adjuvant radiochemotherapy with LV and bolus 5FU was not shown to improve survival, whereas the incidence of severe leucopaenia was significantly higher in the IRI arm.
Collapse
Affiliation(s)
- H P Kalofonos
- Department of Medicine, Division of Oncology, University Hospital, University of Patras Medical School, Rion 26504, Patras, Greece.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Faviou E, Zachari A, Nounopoulos C, Agrafiotis E, Vourli G, Dionyssiou-Asteriou A. Elevation of serum N-terminal pro-brain natriuretic peptide after exercise is an index of myocardial damage or a cytoprotective reflection? J Sports Med Phys Fitness 2008; 48:90-96. [PMID: 18212715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
AIM Recent investigations have suggested the occurrence of transient cardiac dysfunction and reversible myocardial injury in healthy individuals after heavy exercise. Our purpose was to examine if the release of N-terminal pro-brain natriuretic peptide (NT-proBNP) after intense exercise in obviously healthy participants may have cytoprotective and growth-regulating effects or may result from myocardial dysfunction/damage with changes in cTnT as a marker for myocardial cell necrosis during exercise. METHODS In 43 highly-trained male athletes <35 years old, who were examined immediately after exercising as well as 2 days later, 21 age-matched male patients classified as stage-B according to ACC/AHA guidelines and 35 healthy age-matched males, we evaluated NT-proBNP and 3rd generation's cTnT by electrochemiluminescence immunoassay. All participants underwent a detailed cardiac protocol including echocardiography and electrocardiogram (ECG). RESULTS In athletes, cTnT consistently remained <0.01 mg/L after exercising as well as after 2 days. NTproBNP immediately after exercising was 58.27+/-19.48 ng/L, without reaching pathological levels, decreasing 2 days later to 22.93+/-10.22 ng/L. Our patients maintained high levels of NTproBNP, as much as a six-fold increase with reference to the levels of our study's control group and with cTnT <0.01 mg/L. In the control group, cTnT and NTproBNP levels were statistically similar with those of the athletes 2 days after exercising. NT-proBNP as a biological marker can reliably discriminate pathological from physiological cardiac hypertrophy. CONCLUSION A normal plasma concentration of NT-proBNP in consecutive routine check-up, before and after exercise, could minimize the possibility of cardiac dysfunction, whereas persistent elevated plasma concentrations warrant further cardiological evaluation.
Collapse
Affiliation(s)
- E Faviou
- Department of Clinical Biochemistry, Medical School, University of Athens, Attikon University Hospital, Athens, Greece.
| | | | | | | | | | | |
Collapse
|
12
|
Gerolymos M, Koutras A, Kontogeorgou E, Iconomou G, Vourli G, Tsiata E, Makatsoris T, Chrysanthopoulos C, Kalofonos H. Phase II study of irinotecan plus leucovorin and bolus 5 fluorouracil as first or second line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15128 Background: The aim of this study was to evaluate the activity and safety of 5-fluorouracil (5-FU) / leucovorin (LV) and irinotecan as first- or second-line treatment in patients with advanced gastric adenocarcinoma. Methods: Treatment consisted of irinotecan 80 mg/m2 intravenously (i.v.), followed by LV 200 mg/m2 (i.v.) and 5- FU 450 mg/m2 as an i.v. bolus. Treatment was administered weekly for 6 weeks, followed by a 2-week rest period. Results: Thirty-one patients (23 chemo-naïve, 8 chemo-exposed) were enrolled. The overall response rate was 22.6% and the disease control rate was 38.7%. Among the patients who received the regimen as first-line treatment, objective response rate was 30.4% and the disease control rate was 52.1%. However, progression of the disease was recorded in all the patients receiving the combination as second-line chemotherapy. The median time to disease progression (TTP) was 4 months and the median duration of survival was 7 months. The median TTP was 6 months for patients treated with first-line chemotherapy and 2.5 for those who received study treatment as second line. Furthermore, the median survival duration was 8 months and 6 months, respectively. The most frequent grade 4 toxicity was febrile neutropenia. Grade 3 or 4 non-hematological toxicities were rare. There were no treatment-related deaths. Conclusions: The combination of 5-FU/LV and irinotecan as first-line treatment was found to be well tolerated, with efficacy comparable to that of other regimens in advanced gastric cancer. Accordingly, this regimen can be regarded as one of first-line options, particularly in patients who can not tolerate aggressive chemotherapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Gerolymos
- University Hospital of Patras, Rio Patras, Greece
| | - A. Koutras
- University Hospital of Patras, Rio Patras, Greece
| | | | - G. Iconomou
- University Hospital of Patras, Rio Patras, Greece
| | - G. Vourli
- University Hospital of Patras, Rio Patras, Greece
| | - E. Tsiata
- University Hospital of Patras, Rio Patras, Greece
| | | | | | - H. Kalofonos
- University Hospital of Patras, Rio Patras, Greece
| |
Collapse
|
13
|
Samantas E, Rigatos SK, Konstantinopoulou A, Vourli G, Siganaki M, Pectasides D, Pectasides M, Papakostas E, Karagianidis G, Aravantinos G. Darbepoetin Alfa assessment in chemotherapy induced anemia. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.18617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18617 Background: Anemia is a very common complication of cancer and its treatment. Epoetins have been proven effective in correcting anemia in cancer patients resulting to the reduction of the need for blood transfusions and having a positive impact to the quality of life (QoL). Darbepoetin alfa, is a novel erythropoiesis stimulating protein (NESP) with longer half life. Methods: This is a prospective, single-centre, clinical trial. Patients with haemoglobin < 12 g/dl, suffering from cancer (solid tumor or lymphoma), for whom chemotherapy is scheduled for at least 12 weeks and have life expectancy >6 months and performance status ECOG 0–2,are treated with Darbepoetin alfa 150 mg per week subcutaneously for at least 12 weeks. Full blood count should be tested at least every 2 weeks and biochemistry every 4 weeks. QoL was assessed before and after treatment using the FACT-An (Functional Assessment of Cancer Therapy-Anemia) scale. Primary endpoint is the correction of anemia (Hb value above 12 g/dl). Frequency of the demographic and clinical characteristics were reported for the categorical variables, while mean and standard deviation were reported for continuous variables, such as age and Hb levels. Results: Fifty-six (56) patients entered the study, 66% of them female. Median age was 64 years. The more common cancers were colorectal (26.8%) ovarian (17.9%), breast (16.1%), lung (12.5%), and bladder (8.9%). Two thirds of the patients had not received previous chemotherapy. A statistically significant increase for Hb was found between week 0 and 12 [1.48; 95% CI 1.07–1.88; p < 0.001]. The increase was significant from 3rd week onwards. There was no evidence of significant difference in any of the QoL components or for significant change in mean fatigue sub-scale (fatigue, non-fatigue), between the two assessments. Conclusions: Darbepoetin alfa given at 150 mg per week subcutaneously to cancer patients under chemotherapy appears to correct anaemia, but has not positive impact on QoL, within the limits of the sample size of this study. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- E. Samantas
- Agii Anargiri Hospital, Athens, Greece; Hellenic Cooperative Oncology Group Data Office, Athens, Greece; University General Hospital Attikon, Athens, Greece
| | - S. K. Rigatos
- Agii Anargiri Hospital, Athens, Greece; Hellenic Cooperative Oncology Group Data Office, Athens, Greece; University General Hospital Attikon, Athens, Greece
| | - A. Konstantinopoulou
- Agii Anargiri Hospital, Athens, Greece; Hellenic Cooperative Oncology Group Data Office, Athens, Greece; University General Hospital Attikon, Athens, Greece
| | - G. Vourli
- Agii Anargiri Hospital, Athens, Greece; Hellenic Cooperative Oncology Group Data Office, Athens, Greece; University General Hospital Attikon, Athens, Greece
| | - M. Siganaki
- Agii Anargiri Hospital, Athens, Greece; Hellenic Cooperative Oncology Group Data Office, Athens, Greece; University General Hospital Attikon, Athens, Greece
| | - D. Pectasides
- Agii Anargiri Hospital, Athens, Greece; Hellenic Cooperative Oncology Group Data Office, Athens, Greece; University General Hospital Attikon, Athens, Greece
| | - M. Pectasides
- Agii Anargiri Hospital, Athens, Greece; Hellenic Cooperative Oncology Group Data Office, Athens, Greece; University General Hospital Attikon, Athens, Greece
| | - E. Papakostas
- Agii Anargiri Hospital, Athens, Greece; Hellenic Cooperative Oncology Group Data Office, Athens, Greece; University General Hospital Attikon, Athens, Greece
| | - G. Karagianidis
- Agii Anargiri Hospital, Athens, Greece; Hellenic Cooperative Oncology Group Data Office, Athens, Greece; University General Hospital Attikon, Athens, Greece
| | - G. Aravantinos
- Agii Anargiri Hospital, Athens, Greece; Hellenic Cooperative Oncology Group Data Office, Athens, Greece; University General Hospital Attikon, Athens, Greece
| |
Collapse
|
14
|
Faviou E, Vourli G, Zachari A, Nounopoulos C, Dionyssiou-Asteriou A. W12-P-015 Cigarette smoking increases oxidative stress and promotes atherosclerosis. ATHEROSCLEROSIS SUPP 2005. [DOI: 10.1016/s1567-5688(05)80259-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
15
|
Gaki V, Baltas D, Bredakis N, Dimitrakakis C, Louis J, Vourli G, Giannou P, Maragoudakis E, Ghiatas A, Keramopoullos A. Local relapse and systemic recurrence in breast cancer patients. Are they related? EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)90879-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
16
|
Gaki V, Baltas D, Bredakis N, Louis J, Chrisanthakis D, Vourli G, Pavlaki K, Keramopoullous A. Analysis of survival and disease free survival of four hundred and fifty-two lobular carcinomas. Breast 2003. [DOI: 10.1016/s0960-9776(03)80081-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
17
|
|